期刊
CURRENT ALZHEIMER RESEARCH
卷 4, 期 5, 页码 537-540出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156720507783018334
关键词
apolipoprotein E4; Alzheimer's disease; therapy
资金
- NATIONAL INSTITUTE ON AGING [P01AG022074] Funding Source: NIH RePORTER
- NIA NIH HHS [P01 AG022074] Funding Source: Medline
As the major genetic risk factor for Alzheimer's disease, the apolipoprotein (apo) E4 isoform is a promising therapeutic target. ApoE4 likely contributes to Alzheimer's disease pathology by interacting with multiple factors through various pathways. Interactions with the amyloid peptide and the amyloid cascade, for example, may lead to cognitive decline and neurodegeneration. Alternatively, apoE4 might act independently of the amyloid peptide. Our working hypothesis is that apoE has isoform-specific effects on neuronal repair and remodeling. One or more injurious agents could result in neuronal damage, requiring neuronal repair or remodeling. The injurious agents (or second hits) may be genetic, metabolic, or environmental. Potential therapeutic strategies include changing the structure of apoE4 to be more apoE3-like, inhibiting the protease that cleaves apoE4 into toxic fragments, and protecting mitochondria from apoE4 toxicity. Structural features that distinguish apoE4 and apoE3 determine their functional differences and hold the key to understanding how apoE4 is involved in Alzheimer's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据